Principal Financial Group Inc. Sells 19,412 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)

Principal Financial Group Inc. trimmed its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Get Rating) by 3.6% during the 4th quarter, HoldingsChannel reports. The fund owned 526,459 shares of the company’s stock after selling 19,412 shares during the quarter. Principal Financial Group Inc.’s holdings in Denali Therapeutics were worth $14,641,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the stock. Creative Planning boosted its holdings in Denali Therapeutics by 4.4% in the second quarter. Creative Planning now owns 7,075 shares of the company’s stock worth $208,000 after acquiring an additional 295 shares in the last quarter. Amalgamated Bank boosted its holdings in Denali Therapeutics by 2.4% in the third quarter. Amalgamated Bank now owns 15,942 shares of the company’s stock worth $489,000 after acquiring an additional 380 shares in the last quarter. Exchange Traded Concepts LLC boosted its holdings in Denali Therapeutics by 18.8% in the fourth quarter. Exchange Traded Concepts LLC now owns 2,584 shares of the company’s stock worth $72,000 after acquiring an additional 408 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Denali Therapeutics by 0.5% in the first quarter. Rhumbline Advisers now owns 97,145 shares of the company’s stock worth $3,125,000 after purchasing an additional 496 shares during the last quarter. Finally, Rockefeller Capital Management L.P. boosted its position in shares of Denali Therapeutics by 5.4% during the third quarter. Rockefeller Capital Management L.P. now owns 11,834 shares of the company’s stock valued at $362,000 after buying an additional 604 shares during the last quarter. 67.26% of the stock is owned by institutional investors.

Denali Therapeutics Stock Performance

DNLI stock opened at $31.40 on Thursday. The business’s 50-day moving average is $25.59 and its two-hundred day moving average is $27.80. Denali Therapeutics Inc. has a fifty-two week low of $20.76 and a fifty-two week high of $39.43. The company has a market cap of $4.30 billion, a price-to-earnings ratio of -10.94 and a beta of 1.33.

Denali Therapeutics (NASDAQ:DNLI – Get Rating) last posted its quarterly earnings data on Monday, May 8th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.10). Denali Therapeutics had a negative return on equity of 40.01% and a negative net margin of 365.21%. The company had revenue of $35.14 million during the quarter, compared to the consensus estimate of $29.88 million. During the same period last year, the business earned ($0.53) EPS. The firm’s quarterly revenue was down 16.6% compared to the same quarter last year. Equities analysts predict that Denali Therapeutics Inc. will post -3.31 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other news, insider Alexander O. Schuth sold 10,000 shares of the firm’s stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $28.60, for a total value of $286,000.00. Following the transaction, the insider now owns 528,691 shares of the company’s stock, valued at $15,120,562.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Alexander O. Schuth sold 5,102 shares of the stock in a transaction dated Wednesday, April 12th. The stock was sold at an average price of $25.04, for a total transaction of $127,754.08. Following the completion of the sale, the insider now owns 528,691 shares in the company, valued at $13,238,422.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Alexander O. Schuth sold 10,000 shares of the stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $28.60, for a total value of $286,000.00. Following the sale, the insider now owns 528,691 shares of the company’s stock, valued at approximately $15,120,562.60. The disclosure for this sale can be found here. Insiders have sold 15,302 shares of company stock valued at $418,754 over the last quarter. 7.90% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

DNLI has been the topic of several recent analyst reports. Oppenheimer dropped their price objective on Denali Therapeutics from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, March 2nd. Evercore ISI dropped their price objective on Denali Therapeutics from $80.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, February 28th. Morgan Stanley increased their price objective on Denali Therapeutics from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Wednesday, April 12th. SVB Leerink reaffirmed an “outperform” rating and set a $50.00 price objective on shares of Denali Therapeutics in a research report on Monday, January 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $105.00 price objective on shares of Denali Therapeutics in a research report on Thursday, February 23rd. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $52.09.

Denali Therapeutics Company Profile

(Get Rating)

Denali Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.